Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1002558

	registered interest
	date	06/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the ability of the NHS long-term plan to (a) tackle the evolving challenges of cancer and (b) ensure that people are able to access personalised and tailored support after they have finished cancer treatment itself.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	188796
	answer	answer is ministerial correction date of answer 14/11/2018 answer text <p>The NHS Long Term Plan provides an excellent opportunity to look at how cancer and other services can be further improved over the next decade. The plan is currently in development and will be published later in the year.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/11/2018 11:29:49 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

1017502

	registered interest
	date	30/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what proportion of (a) leukaemia, (b) non-Hodgkin lymphoma, (c) Hodgkin lymphoma and (d) myeloma cases were diagnosed at each cancer stage in each of the last five years.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	197620
	answer	answer is ministerial correction date of answer 10/12/2018 answer text <p>This information is not held centrally.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/12/2018 15:38:39 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

1039028

	registered interest
	date	10/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Asparaginase
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether Erwinase will be available for the treatment for children with acute lymphoblastic leukaemia between January 2019 and March 2019; and if he will make a statement.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	207238
	answer	answer is ministerial correction date of answer 18/01/2019 answer text <p>Erwinase is produced by Porton Biopharma Ltd (PBL) and is licensed and distributed by Jazz Pharmaceuticals under a global licencing agreement.</p><p> </p><p>Due to increased demand for Erwinase and because PBL are manufacturing at capacity, until increases in capacity are brought into beneficial use there will be occasional stock-outs.</p><p> </p><p>The product is currently in stock in the United Kingdom. The Department has been informed, it is likely there will be a short stock-out in early February 2019 and then a further batch is planned to be released to Jazz Pharmaceuticals, who are responsible for the packaging/distribution and allocation of worldwide product supply, anticipated to reach the UK market by mid-February 2019 which should last until the end of March 2019.</p><p> </p><p>The Department and Public Health England (PHE) are in close contact with, and have been kept informed by the PBL management of short periods of interrupted supply. PBL have and will be implementing a series of initiatives to increase capacity and better supply the market in both the short and long term. PBL are fully aware of the consequences that the unavailability of Erwinase has on patients and are absolutely committed to working with all involved to resolve any issues and be able to supply this critical medicine.</p><p> </p><p>The Department and PHE will continue to monitor the situation closely.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/01/2019 12:18:00 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

1050100

	registered interest
	date	28/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 March 2018 to Question 134294 on Haematological Cancer, when he plans for the evaluation of the rapid diagnostic centres to be published; and he plans for that evaluation to inform the national roll-out of the centres as proposed in the NHS Long-Term Plan.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	213321
	answer	answer is ministerial correction date of answer 05/02/2019 answer text <p>Ten multi-disciplinary diagnostic centres are being piloted through the Accelerate, Co-ordinate, Evaluate (ACE) partnership between Cancer Research UK, Macmillan Cancer Support and NHS England. This pilot programme will end in March 2019. Early findings from those sites informed the plans for roll out of the Rapid Diagnostic Centres as part of the NHS Long Term Plan.</p><p> </p><p>During 2019/20, the ACE Programme will share further evaluation from the pilot centres. The findings will continue to inform plans for expansion of the Rapid Diagnostic Centres, alongside work being led by Cancer Alliances to improve early diagnosis.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/02/2019 15:31:33 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

1050101

	registered interest
	date	28/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Asparaginase
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 18 January 2019 to Question 207238 on Asparaginase, what steps Porton Biopharma will take to increase capacity of erwinase and better supply the (a) UK and (b) world market for the remainder of 2019.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	213322
	answer	answer is ministerial correction date of answer 05/02/2019 answer text <p>Porton Biopharma Ltd (PBL) are implementing a series of initiatives to increase capacity and supply in both the short and long term. These include the following:</p><p>- Extending operational activities to 24 hours a day, seven days a week to maximise fermentation of the product;</p><p>- Implementing an ongoing capital programme including construction of a new pharmaceutical fermentation facility. The facility was completed in April 2018 and is currently undergoing testing; it has an increased capacity fermentation suite which will enable PBL to manufacture at larger scale and is due to start producing product Q3 2019 for regulatory approval to market;</p><p>- A new filling and freeze-drying building was completed in February 2016. The installation of a new filling line which covers the entire process, including vial washing, filling, stoppering and freeze drying. The new line has been designed with systems which monitor all critical parameters throughout the process to accelerate batch release and will accommodate increased capacity. The beneficial use of this and the fermentation facility will coincide to maximise increased product output; and</p><p>- Sourcing replacement suppliers, including for new stoppers and new vials for the product, ensuring that maximum batch sizes can be achieved with minimal product rejects. This programme is complete.</p><p> </p><p>PBL has made significant investments into increasing product capacity and will continue to release future batches as soon as they become available to Jazz Pharmaceuticals (who are responsible for the packaging/distribution and allocation of worldwide product supply).</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/02/2019 15:09:48 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

1060965

	registered interest
	date	14/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Counselling
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans the Government has to ensure that people with cancer are able to access psychological and emotional support.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	909320
	answer	answer is ministerial correction date of answer 19/02/2019 answer text <p>By 2021, every person diagnosed with cancer will have access, where appropriate, to personalised care, including a needs assessment, a care plan and health and wellbeing information and support. The needs assessment guides a conversation about the person’s holistic needs (physical, psychosocial, financial and social) in order to identify any concerns, including psychological and emotional.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/02/2019 17:25:31 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

746126

	registered interest
	date	28/06/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, when he expects the Cancer Transformation Fund to be made available to support the Cancer Recovery Package and the cancer stratified follow-up pathways.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	1543
	answer	answer is ministerial correction date of answer 04/07/2017 answer text <p>In December 2016, Cancer Alliances were invited to submit bids against a £200 million transformation fund (for 2017/18 and 2018/19) to support delivery of early diagnosis and implementation of the Recovery Package and stratified follow-up pathways. Based on an assessment of the bids, NHS England has decided to take a phased approach to releasing the funding over the course of 2017/18.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 04/07/2017 11:22:52 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

765286

	registered interest
	date	06/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Transplant Surgery: Stem Cells
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will discuss with NHS England the necessity for a review of the care and support that patients receive after a stem cell transplant.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	105453
	answer	answer is ministerial correction date of answer 16/10/2017 answer text <p>Post-transplant care for patients is important. NHS England’s Specialised Commissioning team and Clinical Reference Group for Blood and Marrow Transplants (BMT) are undertaking work to map care needs post-100 days.</p><p> </p><p>There are no current plans to review the responsibilities of services commissioned by NHS England and clinical commissioning groups (CCGs) for BMT at this time. NHS England will be assessing BMT in more detail over the next 18 months and will take the opportunity to further support improved pathway planning and commissioning of services that it and CCGs fund.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/10/2017 16:36:57 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

765287

	registered interest
	date	06/10/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Transplant Surgery: Stem Cells
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, for what reason responsibility for commissioning services following a stem cell transplant from NHS England to clinical commissioning groups after 100 days.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	105452
	answer	answer is ministerial correction date of answer 16/10/2017 answer text <p>The Manual for Prescribed Specialised Services describes which elements of specialised services are commissioned by NHS England and which are commissioned by clinical commissioning groups (CCGs):</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2017/10/prescribed-specialised-services-manual-2.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2017/10/prescribed-specialised-services-manual-2.pdf</a></p><p>Due to the small number of patients involved, the cost of the transplant episode and the small number of transplant experts, Blood and Bone Marrow Transplantation (BMT) is defined as a prescribed specialised service. NHS England is responsible for commissioning and funding the transplant related care which takes place 30 days before transplant and continues until 100 days post-transplant. After 100 days post-transplant, commissioning responsibility for the routine follow-up of patients switches from NHS England to CCGs, as outlined in the Manual.</p><p>In the event that transplant patients experience serious complications post-transplant, elements of their care would likely continue to be planned, organised and funded by NHS England specialised commissioning. For example, if a patient requires Extracorporeal Photopheresis which is a treatment for acute and chronic graft versus host disease following transplantation, NHS England commissions this care post-transplant.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/10/2017 16:39:07 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

786830

	registered interest
	date	10/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	General Practitioners
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to increase capacity in general practice in (a) Crawley constituency and (b) England.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	112399
	answer	answer is ministerial correction date of answer 20/11/2017 answer text <p>In April 2016, the General Practice Forward View set out a package of investment in general practice. This included a number of reforms which will increase capacity in general practice through recruitment and retention of general practitioners (GPs) and the wider workforce, and investment in extended access to GP services and the Time for Care programme.</p><p> </p><p>By 2020 the Government has committed to 5,000 additional GPs and 5,000 other staff in general practice; and by March 2019 everyone having access to GP services, including sufficient routine appointments at evenings and weekends to meet locally determined demand.</p><p> </p><p>The Time for Care programme will spread awareness of innovations that will help release capacity in general practice and facilitate local change programmes to implement them. Examples of these innovations include active signposting and developing the team. It is estimated that most practices can expect to release about 10% of GP time. The Time for Care programme provides support for groups of practices to implement their choice of the actions. To date, this has covered 115 clinical commissioning groups, available to 3,974 practices.</p><p> </p><p>In 2016/17 £2,000,000 of funding was awarded to NHS Crawley Clinical Commissioning Group to improve local GP practice resilience and sustainability and improve access to local GP services for patients.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/11/2017 12:25:28 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith